Evidence map›Paper›PMID 30298184›Full record

ReviewThe journal of prevention of Alzheimer's disease2018

Pimavanserin: Potential Treatment For Dementia-Related Psychosis.

J Cummings, C Ballard, P Tariot, R Owen, E Foff, J Youakim, J Norton, S Stankovic

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of prevention of Alzheimer's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Biased signalingActa pharmaceutica Sinica. B · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Lewy Body Dementia.Continuum (Minneapolis, Minn.) · 2024
    Review
  8. Article
  9. Article
  10. Mirtazapine Monotherapy for Antipsychotics-refractory Psychosis in a Patient with Very-late-onset Schizophrenia-like Psychosis: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. Functional Disabilities and Psychiatric Symptoms in Primary Progressive Aphasia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

J CummingsJeffrey Cummings MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W. Bonneville Ave, Las Vegas, NV, USA, cumminj@ccf.org.
C Ballard
P Tariot
R Owen
E Foff
J Youakim
J Norton
S Stankovic
Acadia Pharmaceuticals (United States) · USCleveland Clinic · USUniversity of Arizona · USUniversity of Exeter · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychosis is common across dementia types with a prevalence of 20% to 70%. Currently, no pharmacologic treatment is approved for dementia-related psychosis. Atypical antipsychotics are frequently used to treat these disorders, despite significant safety concerns. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved in the U.S. for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - Parkinson's disease (SAPS-PD) scores vs. placebo. In a subgroup analysis of patients with cognitive impairment (MMSE score ≥21 but ≤24), the observed improvement on the SAPS-PD with pimavanserin (N=50) was also significant (p=0.002) and larger than in the overall study population without an adverse effect on cognition. In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0.045) improved psychosis at Week 6 vs. placebo on the NPI-NH Psychosis Score (PS). In a prespecified subgroup of patients with a baseline NPI-NH PS ≥12, a substantively larger treatment effect (p=0.011) was observed vs. participants with NPI-NH PS <12. The results of these studies in cognitively impaired patients with PDP provided the scientific foundation for an ongoing study of pimavanserin for treating patients with dementia-related psychosis associated with the most common neurodegenerative disorders. The study uses a relapse-prevention design with the endpoint of time-to-relapse of psychosis to evaluate the long-term efficacy and safety of pimavanserin as a potential treatment for hallucinations and delusions of dementia-related psychosis.

Indexed as

Alzheimer DiseaseClinical Trials as TopicDementiaHumansMental Status and Dementia TestsParkinson DiseasePiperidinesPsychotic DisordersSerotonin 5-HT2 Receptor AntagonistsSeverity of Illness IndexTreatment OutcomeUreapimavanserinPiperidinesSerotonin 5-HT2 Receptor AntagonistsUreaAlzheimer’s diseaseDementiadementia with Lewy bodiesfrontotemporal dementiaParkinson’s diseasepsychosis

Identifiers

PMID30298184
PMCPMC6413822
OpenAlexW2889655735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.